Patient info Open main menu

Brivaracetam Glenmark 75 mg film-coated tablets – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
75 mg
Contains active substance:

Patient leaflet - Brivaracetam Glenmark 75 mg film-coated tablets

1. What Brivaracetam Glenmark is and what it is used for

What Brivaracetam Glenmark is

Brivaracetam Glenmark contains the active substance brivaracetam. It belongs to a group of medicines called ‘anti-epileptics’. These medicines are used to treat epilepsy.

What Brivaracetam Glenmark is used for

  • Brivaracetam Glenmark is used in adults, adolescents

    and children from 2 years of age.

  • It is used to treat a type of epilepsy that has partial

    seizures with or without a secondary generalisation.

  • Partial seizures are fits that start by only affecting one

    side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a ‘secondary generalisation’.

  • You have been given this medicine to lower the number

    of fits (seizures) you have.

  • Brivaracetam Glenmark is used together with other

    medicines for epilepsy.

2. What you need to know before you take Brivaracetam Glenmark

Do not take Brivaracetam Glenmark if:

  • you are allergic to brivaracetam, other similar chemical

    compounds as levetiracetam or piracetam or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before taking Brivaracetam Glenmark.

Warnings and precautions

Talk to your doctor or pharmacist before taking Brivaracetam Glenmark if:

  • You have thoughts of harming or killing yourself. A

    small number of people being treated with anti-epileptic medicines such as Brivaracetam have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.

  • You have liver problems - your doctor may need to adjust

    your dose.

Children

Brivaracetam Glenmark is not recommended for use in children under 2 years of age.

Other medicines and Brivaracetam Glenmark

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, tell your doctor if you are taking any of the following medicines – this is because your doctor may need to adjust your Brivaracetam Glenmark dose:

  • Rifampicin - a medicine used to treat bacterial infections.
  • St John’s wort (also known as Hypericum perforatum) - a

    herbal medicine used to treat depression and anxiety as well as other conditions.

Brivaracetam Glenmark with alcohol

  • Combining this medicine with alcohol is not

    recommended.

  • If you drink alcohol while taking Brivaracetam Glenmark

    the negative effects of alcohol may be increased.

Pregnancy and breast-feeding

Fertile women should discuss the use of contraceptives with the doctor.

If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

It is not recommended to take Brivaracetam Glenmark if you are pregnant, as the effects of Brivaracetam Glenmark on pregnancy and the unborn baby are not known.

It is not recommended to breast-feed your baby while taking Brivaracetam Glenmark, as Brivaracetam Glenmark passes into breast milk.

Do not stop treatment without talking to your doctor first. Stopping treatment could increase your seizures and harm your baby.

Driving and using machines

  • You may feel sleepy, dizzy or tired while taking

    Brivaracetam Glenmark.

  • These effects are more likely at the start of the treatment or after a dose increase.
  • Do not drive, cycle or use any tools or machines until you know how the medicine affects you.

Brivaracetam Glenmark contains sodium

This medicine contains less than 1 mmol sodium (23mg) per tablet, that is to say essentially ‘sodium free’.

3. How to take Brivaracetam Glenmark

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Other form(s) of this medicine may be more suitable for certain patients e.g. children (if tablets cannot be swallowed in whole, for example); ask your doctor or pharmacist.

You will take Brivaracetam Glenmark together with other medicines for epilepsy.

How much to take

Your doctor will work out the right daily dose for you. Take the daily dose in two equal divided doses, approximately 12 hours apart.

Adolescents and children weighing 50 kg or more, and adults

  • The recommended dose is from 25 mg to 100 mg taken twice a day. Your doctor may then decide to adjust your dose to find the best dose for you.

Adolescents and children weighing from 20 kg to less than 50 kg

  • The recommended dose is from 0.5 mg to 2 mg for each kg of bodyweight, taken twice a day. Your doctor may then decide to adjust your dose to find the best dose for you.

Children weighing from 10 kg to less than 20 kg

  • The recommended dose is from 0.5 mg to 2.5 mg for each kg of bodyweight, taken twice a day. Your child’s doctor may then decide to adjust your child’s dose to find the best dose for your child.

People with liver problems

If you have problems with your liver:

  • As an adolescent or child weighing 50 kg or more, or as an adult, the maximum dose you will take is 75 mg twice a day.
  • As an adolescent or child weighing from 20 kg to less than 50 kg, the maximum dose you will take is 1.5 mg for each kg of bodyweight twice a day.
  • As a child weighing from 10 kg to less than 20 kg, the maximum dose your child will take is 2 mg for each kg of bodyweight twice a day.

How to take Brivaracetam Glenmark tablets

  • Swallow the tablets whole with a glass of liquid.
  • The medicine may be taken with or without food.

How long to take Brivaracetam Glenmark for

Brivaracetam Glenmark is a long-term treatment – keep taking Brivaracetam Glenmark until your doctor tells you to stop.

If you take more Brivaracetam Glenmark than you should

If you have taken more Brivaracetam Glenmark than you should, talk to your doctor. You may feel dizzy and sleepy. You may also have any of the following symptoms: feeling sick, a feeling of ‘spinning’, problems of keeping your balance, anxiety, feeling very tired, irritability, being aggressive, not being able to sleep, depression, thoughts or attempts of harming or killing yourself.

If you forget to take Brivaracetam Glenmark

  • If you miss a dose take it as soon as you remember.
  • Then take your next dose at the time you would normally take it.
  • Do not take a double dose to make up for a forgotten dose.
  • If you are not sure what to do, ask your doctor or pharmacist.

If you stop taking Brivaracetam Glenmark

  • Do not stop taking this medicine unless your doctor tells you to. This is because stopping treatment could increase the number of fits you have.

Package leaflet: Information for the patient

Brivaracetam Glenmark 10 mg film-coated tablets Brivaracetam Glenmark 25 mg film-coated tablets Brivaracetam Glenmark 50 mg film-coated tablets Brivaracetam Glenmark75 mg film-coated tablets Brivaracetam Glenmark 100 mg film-coated tablets

brivaracetam

  • If your doctor asks you to stop taking this medicine they

    will lower your dose gradually. This helps to stop your fits coming back or getting worse.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common: may affect more than 1 in 10 people

  • feeling sleepy or dizzy

Common: may affect up to 1 in 10 people

  • flu
  • feeling very tired (fatigue)
  • convulsion, a feeling of ‘spinning’ (vertigo)
  • feeling and being sick, constipation
  • depression, anxiety, not being able to sleep (insomnia),

    irritability

  • infections of the nose and throat (such as the ‘common

    cold’), cough

  • decreased appetite

Uncommon: may affect up to 1 in 100 people

  • allergic reactions
  • abnormal thinking and/or loss of touch with reality

    (psychotic disorder), being aggressive, nervous excitement (agitation)

  • thoughts or attempts of harming or killing yourself: tell

    your doctor straight away

  • a decrease in white blood cells (called ‘neutropenia’) -

    shown in blood tests

Additional side effects in children

Common: may affect up to 1 in 10 people

  • restlessness and hyperactivity (psychomotor

    hyperactivity)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Brivaracetam Glenmark

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is

    stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

  • This medicinal product does not require any special

    storage conditions.

  • Do not throw away any medicines via wastewater or

    household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Brivaracetam Glenmark contains

The active substance is brivaracetam.

Each film-coated tablet contains 10 mg, 25 mg, 50 mg, 75 mg, or 100 mg brivaracetam.

The other ingredients are:

Core

Cellulose, microcrystalline, Starch pregelatinized, Croscarmellose sodium, magnesium stearate

Coating

  • 10 mg film-coated tablets: poly(vinyl alcohol), calcium

    carbonate, macrogol (3350), talc.

  • 25 mg film-coated tablets: poly(vinyl alcohol), calcium

    carbonate, macrogol (3350), talc, iron oxide yellow (E172), iron oxide black (E172).

  • 50 mg film-coated tablets: poly(vinyl alcohol), calcium

    carbonate, macrogol (3350), talc, iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172).

  • 75 mg film-coated tablets: poly(vinyl alcohol), calcium

    carbonate, macrogol (3350), talc, iron oxide red (E172), iron oxide black (E172).

  • 100 mg film-coated tablets: poly(vinyl alcohol), calcium

    carbonate, macrogol (3350), talc, iron oxide yellow (E172), iron oxide black (E172).

What Brivaracetam Glenmark looks like and contents of the pack

Brivaracetam Glenmark 10 mg are white to off-white, round, biconvex, film-coated tablets of 5.5 mm in diameter and debossed with “10” on one side.

Brivaracetam Glenmark 25 mg are grey, oval, biconvex, film-coated tablets of 9 mm x 5.0 mm and debossed with “25” on one side.

Brivaracetam Glenmark 50 mg are yellow, oval, biconvex, film-coated tablets of 11.65 mm x 6.5 mm and debossed with “50” on one side.

Brivaracetam Glenmark 75 mg are pink, oval, biconvex, film-coated tablets of 13.0 mm x 7.25 mm and debossed with “75” on one side.

Brivaracetam Glenmark 100 mg are grey-green, oval, biconvex, film-coated tablets of 14.5 mm x 8.15 mm and debossed with “100” on one side.

Brivaracetam Glenmark tablets are packaged in blister packs supplied in cardboard boxes containing 14, 56 or 100x1 film-coated tablets or in multipacks of 168 (2packs of 84 for 10 mg,

25 mg, 50 mg and 75 mg or 3 packs of 56 for 100 mg) film-coated tablets

All packs are available in Aluminium/Aluminium (OPA/ aluminium foil/ PVC) blister.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Glenmark Pharmaceuticals Europe Limited

Laxmi House, 2-B Draycott Avenue, Kenton, Harrow, Middlesex

HA3 0BU, United Kingdom

Manufacturer

Glenmark Pharmaceuticals Europe Limited

Building 2, Croxley Green Business Park

Croxley Green, Hertfordshire

WD18 8YA, United Kingdom

For information in large print, tape, CD or Braille, telephone 0800 198 5000

Please be ready to give the following information:

Product name Reference Number

Brivaracetam Glenmark 10 mg

film-coated tablets

PL 25258/0437

Brivaracetam Glenmark 25 mg

film-coated tablets

PL 25258/0438

Brivaracetam Glenmark 50 mg

film-coated tablets

PL 25258/0439

Brivaracetam Glenmark75 mg

film-coated tablets

PL 25258/0440

Brivaracetam Glenmark 100 mg

film-coated tablets

PL 25258/0441

This leaflet was last revised in December 2025

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 25258/0440

Last revision stated in the text: December 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Brivaracetam Glenmark 75 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Brivaracetam
Strength 75 mg
Pharmaceutical form Oral tablet
Pink, oval, biconvex film-coated tablets of 13.0 x 7.25 mm debossed with “75” on one side.
How is it taken Oral
Excipients Cellulose, microcrystalline, Starch Pregelatinized, Croscarmellose sodium, Magnesium stearate, Poly(vinyl alcohol) part. hydrolyzed, Calcium Carbonate, Macrogol, Talc, Black iron oxide, Iron oxide red
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 36 months
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Antiepileptics, other antiepileptics
  1. N Nervous system drugs
    1. N03 Antiepileptics
      1. N03A Antiepileptics
        1. N03AX Other antiepileptics
          1. N03AX23 brivaracetam
Marketing authorisation PL 25258/0440 (first authorised 22 December 2025)
Marketing authorisation holder Glenmark Pharmaceuticals Europe Limited
Codes BNF 04080100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.